As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close ...

Adding durvalumab to Bacillus Calmette-Guérin (BCG) induction (I) and maintenance (M) does not meaningfully improve patient-reported outcomes (PROs) at 5 years among patients with non-muscle invasive ...

Traders remain focused on Anktiva’s potential label expansion for papillary bladder cancer, with an FDA decision date set for ...

Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, ...

BCG vaccine altered immune responses and modified amyloid-beta, study shows ...

Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of ...

NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.

Detailed price information for Cg Oncology Inc (CGON-Q) from The Globe and Mail including charting and trades.

Edison Investment Research said oncology still offers “continued opportunities” across immuno-oncology, targeted therapies ...

BOSTON & MONTREAL, June 15, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, ...

Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from ...

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have ...